Fingerpaint Group Acquires The MYND Group, Bolstering Market Access Capabilities
Fingerpaint Group, a collective of healthcare companies providing commercialization solutions, is expanding its market access capabilities with the acquisition of The MYND Group, a strategic market access marketing company specializing in pharmaceuticals and biologics.
The MYND Group will enhance Fingerpaint's market access strategy, research, and launch experience. Jonathan Magid will continue leading The MYND Group as Managing Director, reporting to Brannon Cashion, President of Specialty Services at Fingerpaint Group.
Fingerpaint Group has seen significant growth since partnering with private equity firm Knox Lane in 2020.
Reference: Fingerpaint Group Acquires The MYND Group, Bolstering Its Robust Market Access Capabilities. April 4, 2023 / Fingerpaint
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
